Evotec said that the advancement of EVT 101 into Phase II study is a part of an alliance between Evotec and Roche.
Under this alliance Evotec is responsible for conducting Phase II studies for EVT 101, a compound originally discovered by Roche and developed from discovery stages through clinical studies by Evotec.
Evotec and Roche said that the main objective of studying EVT 101 is to evaluate the safety and tolerability of EVT 101 while also exploring the efficacy of this intervention.
EVT 101’s Phase II study is expected to involve approximately 100 patients suffering from treatment-resistant depression. Treatment-resistance of patients is expected to be confirmed in a 6-week prospective antidepressant treatment phase preceding the actual 4-week double-blind treatment.
Werner Lanthaler, CEO of Evotec, said: “The clinical development of EVT 101 is addressing an area of unmet medical need. We are happy to have Roche for this development with us.”